Clenil UDV, ampoules 800 µg/2 ml, 20 pcs.

Composition

1 ampoule contains:

Beclomethasone dipropionate 800 mcg.

Auxiliary substances:

polysorbate 20,

sorbitan laurate,

sodium chloride,

purified water.

Pharmacological action

Clenil UDV has an anti-inflammatory and anti-allergic effect. It inhibits the release of inflammatory mediators, increases the production of lipomodulin, a phospholipase A inhibitor, reduces the release of arachidonic acid, and inhibits prostaglandin synthesis. Prevents the marginal accumulation of neutrophils, reducing the formation of inflammatory exudate and the production of lymphokines, inhibits the migration of macrophages, which leads to a slowdown in the processes of infiltration and granulation.

Increases the number of active a-adrenergic receptors, neutralizes their desensitization, restores the patient’s response to bronchodilators, allowing to reduce the frequency of their use.

Under the influence of Beclomethasone, the number of mast cells in the bronchial mucosa decreases, epithelial edema and mucus secretion by the bronchial glands decreases. Causes relaxation of the smooth muscles of the bronchi, reduces their hyperreactivity and improves the function of external respiration. It does not have mineralocorticoid activity. In therapeutic doses, it does not cause side effects characteristic of systemic corticosteroids. When applied intranasally, it eliminates edema, hyperemia of the nasal mucosa. The therapeutic effect usually develops after 5-7 days of a course of Beclomethasone administration. When applied externally and topically, it has an anti-allergic and anti-inflammatory effect.

Indications

For inhalation use: treatment of bronchial asthma (including those with insufficient effectiveness of bronchodilators and / or sodium cromoglycate, as well as hormone-dependent bronchial asthma of severe course in adults and children).

For intranasal use: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever rhinitis, vasomotor rhinitis.

For external and topical use: in combination with antimicrobial agents-infectious and inflammatory diseases of the skin and ear.

Use during pregnancy and lactation

Use in the second and third trimesters of pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus. Newborns whose mothers received Beclomethasone during pregnancy should be carefully evaluated for adrenal insufficiency.

If it is necessary to use during lactation, the question of stopping breastfeeding should be decided.

Contraindications

-Severe attacks of bronchial asthma that require intensive care. – Tuberculosis. – Candidiasis of the upper respiratory tract. – I trimester of pregnancy. – Hypersensitivity to Beclomethasone.

Interaction

Concomitant use of Beclomethasone with other corticosteroids for systemic or intranasal administration may increase suppression of the adrenal cortex.

Previous inhaled use of beta-adrenostimulants may increase the clinical efficacy of Beclomethasone.

How to take, course of administration and dosage

For adults, when inhaled, the average dose is 400 mcg/day, the frequency of use is 2-4 times/day. If necessary, the dose can be increased to 1 g / day. For children, a single dose is 50-100 mcg, the frequency of use is 2-4 times/day.

When administered intranasally, the dose is 400 mcg / day, the frequency of application is 1-4 times/day.

With external and topical application, the dose depends on the indications and the dosage form of the drug used.

Special instructions

Beclomethasone is not intended for the relief of acute asthmatic attacks. It should also not be used for severe asthma attacks that require intensive care. The recommended route of administration for the dosage form used should be strictly followed.

Beclomethasone should be used with extreme caution and under the close supervision of a doctor in patients with adrenal insufficiency.

Transfer of patients who are constantly taking corticosteroids inside, to inhaled forms can be made only in a stable condition.

If paradoxical bronchospasm is likely to develop, bronchodilators (for example, salbutamol) are inhaled 10-15 minutes before the introduction of Beclomethasone.

If candidiasis of the oral cavity and upper respiratory tract develops, local antifungal therapy is indicated without stopping treatment with Beclomethasone. Infectious and inflammatory diseases of the nasal cavity and paranasal sinuses with the appointment of appropriate therapy are not a contraindication for treatment with Beclomethasone.

Preparations for inhalation use containing 250 mcg of Beclomethasone in 1 dose are not intended for children under 12 years of age.

Form of production

Suspension for inhalation.

Storage conditions

Store at a temperature not exceeding 25 ° C, in the original packaging to protect from light, away from heating devices, in an upright position.

Shelf

life is 2 years.

Active ingredient

Beclomethasone

Conditions of release from pharmacies

By prescription

Dosage form

suspension for inhalation

Weight

Weight: 104 gr.